44 research outputs found

    Recent metabolomic developments for antimalarial drug discovery.

    Full text link
    peer reviewedMalaria is a parasitic disease that remains a global health issue, responsible for a significant death and morbidity toll. Various factors have impacted the use and delayed the development of antimalarial therapies, such as the associated financial cost and parasitic resistance. In order to discover new drugs and validate parasitic targets, a powerful omics tool, metabolomics, emerged as a reliable approach. However, as a fairly recent method in malaria, new findings are timely and original practices emerge frequently. This review aims to discuss recent research towards the development of new metabolomic methods in the context of uncovering antiplasmodial mechanisms of action in vitro and to point out innovative metabolic pathways that can revitalize the antimalarial pipeline

    Détection et quantification simultanée de la gastrine 17 et 34 sous forme sulfatée et non-sulfatée par LC-MS/MS dans le plasma humain

    Full text link
    editorial reviewedGastrin, secreted by G cells, plays a crucial role in digestion and has diverse functions including regulation of the intestinal epithelium and stomach growth. Gastrin peptides are derived from progastrin. Peptides G17 and G34 are the most abundant in the blood. Both of them may be sulfated. Current gastrin measurement relies on the DIAsource RIA kit, however it displays cross-reactivity issues. Therefore, we developed a LC-MS/MS method to quantify both sulfated and non-sulfated G17 and G34 forms

    Préparation des canaux courbes (étude expérimentale de deux systèmes de préparation endodontique en rotation continue)

    No full text
    BORDEAUX2-BU Sci.Homme/Odontol. (330632102) / SudocREIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

    From Metabolomics to Identification of a new therapeutic approach for Age-Related Macular Degeneration (AMD)

    Full text link
    Age-related macular degeneration (AMD) is the leading cause of vision loss in the western world among people aged 50 or older. 90% of all vision loss due to AMD result from the exudative form, which is characterized by choroidal neovascularization (CNV). Age-related changes that induce pathologic CNV are incompletely understood and critical issues remain to be addressed. Metabolomics is defined as the comprehensive study of endogenous metabolites changes in various biological systems. This newly emerging “omic” science provides a unique opportunity to correlate variation of the metabolome with pathological occurrence or progression and/or to identify metabolites that are implicated in the disease. We apply a 1H NMR metabolomics approach on sera collected from AMD patient and healthy volunteers and form a mice model of laser-induced CNV which mimics the effect of exudative AMD. After post-processing treatments, the different spectra were analyzed by statistical discriminant methodologies (PCA, ICA, PLS-DA, O-PLS-DA). These approaches allow the differentiation between control and AMD patients and between laser-induced mice and the control mice group. Moreover, the same discriminating spectral zones have been identified in human and mice model, leading to the emergence of different putative biomarkers. Among these markers, lactate emerges as a key metabolite in both settings. Mechanistically, lactate produced locally and by inflammatory cells, plays a critical role in the onset of the inflammatory and angiogenic phases. In mice model of laser-induced CNV, normalization of circulating lactate by dichloroacetate a pyruvate dehydrogenase kinase (PDK) inhibitor, decreases CNV development. Our data support the innovative concept of lactate as a parainflammation- and angio-metabolite associated to AMD and CNV progression. Moreover, control of blood lactate level via inhibition of PDK provides new options for the treatment of exudative AMD. This study demonstrates the ability of metabolomics for drug target discovery and opens new perspectives for AMD treatment and patient follow-up
    corecore